Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ultrafine concentrated ambient particles (UCAPs) are environmental particulate matter with an aerodynamic diameter of less than 0.1 micrometers, collected from ambient air and concentrated for clinical research purposes. Developed and utilized by researchers at the University of California, Los Angeles (UCLA), UCAPs serve as a standardized challenge agent to study the respiratory and systemic health effects of air pollution. When administered via nasal challenge, these particles induce oxidative stress and trigger the release of pro-inflammatory mediators in the nasal mucosa, allowing for the characterization of cellular inflammation and its impact on individuals with allergic rhinitis or other respiratory conditions. The particles are typically concentrated using specialized systems like the Versatile Aerosol Concentration Enrichment System (VACES).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ultrafine Concentrated Ambient Particles.